<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03718754</url>
  </required_header>
  <id_info>
    <org_study_id>1636/2018</org_study_id>
    <nct_id>NCT03718754</nct_id>
  </id_info>
  <brief_title>En-bloc vs Conventional Resection of Primary Bladder Tumor</brief_title>
  <acronym>eBLOC</acronym>
  <official_title>En-bloc vs Conventional Resection of Primary Bladder Tumor: Prospective Randomized Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David D'Andrea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on current evidence, we hypothesize that eTURB represents an improvement in the
      surgical management of NMIBC. The resection is more precise and complete compared to cTURB.
      Moreover, the quality of an en-bloc specimen, including the tumor with its adjacent bladder
      wall layers, allows an accurate pathological review which leads to correct risk allocation
      and therapy.

      To answer these questions, we designed a RCT comparing eTURB with cTURB. Primary outcome of
      our study will be the accuracy of pathological staging assessment measured by the presence of
      detrusor muscle in the specimen as a surrogate parameter for quality and completeness of
      resection.

      Secondary end point will be completeness of tumor removal reflected by cancer persistence
      within 3 months of the resection.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2019</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The pathological staging assessment for eTURB compared to cTURB</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Residual disease within 3 months after initial TURB</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of obturator reflex</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operative time</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day complications</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Upstaging of disease upon second look transurethral resection surgery</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">476</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>En-Bloc TURB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional TURB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>En-Bloc TURB</intervention_name>
    <description>En-bloc resection will be performed at each center based on local clinical practice and available instruments. Laser resection, hydrodissection with HybridKnife® or electric resection are allowed. All procedures, including cTURB, must be performed with an imaging enhancing technique (PDD / NBI at surgeon's discretion). After resection, a single intravesical instillation of 40mg Mitomycin-C will be performed if clinically feasible.</description>
    <arm_group_label>En-Bloc TURB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Conventional TURB</intervention_name>
    <description>En-bloc resection will be performed at each center based on local clinical practice and available instruments. After resection, a single intravesical instillation of 40mg Mitomycin-C will be performed if clinically feasible.</description>
    <arm_group_label>Conventional TURB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Subjects must meet all the following inclusion criteria to participate in this study:

          -  Diagnosis by cystoscopy of primary papillary non-muscle invasive bladder urothelial
             carcinoma (cTa, cT1)

          -  Imaging examinations shows that the bladder muscle has not been affected, no lymph
             node metastasis or distant metastasis;

          -  Diameter of tumor &lt;3cm

          -  Number of lesions ≤3 (The position of small lesions relatively concentrated as one
             place)

          -  Patients who agree to eTURB or cTURB surgery, and will be effected to the
             postoperative follow-up treatment such as conventional infusion after the operation

        Exclusion Criteria

          -  Pure carcinoma in situ

          -  Contraindications to surgery (i.e. bladder fibrosis)

          -  Diameter of tumor &gt;3cm

          -  Number of lesions &gt;3

          -  Poor performance status making a surgical intervention too risky

          -  Life expectancy of less than one year

          -  Patient refused to participate

          -  Pregnancy

          -  History of upper urinary tract malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shahrokh Shariat, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Shahrokh.shariat@meduniwien.ac.at</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David D'Andrea, M.D.</last_name>
    <phone>00434040026150</phone>
    <email>david.dandrea@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Francesco Soria, M.D.</last_name>
    <phone>00434040026150</phone>
    <email>francesco.soria@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David D'Andrea, M.D.</last_name>
      <email>david.dandrea@meduniwien.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Francesco Soria, M.D.</last_name>
      <email>francesco.soria@meduniwien.ac.at</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>October 23, 2018</study_first_submitted>
  <study_first_submitted_qc>October 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2018</study_first_posted>
  <last_update_submitted>June 25, 2019</last_update_submitted>
  <last_update_submitted_qc>June 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>David D'Andrea</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

